Skip to main content

Advertisement

SpringerLink
Log in

Niacin, lipids, and heart disease

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Niacin is the most effective medication in current clinical use for increasing high-density lipoprotein (HDL) cholesterol. It has the broadest effect on the lipid profile, reducing all atherogenic apolipoprotein (apo) B and increasing all antiatherogenic apo AI-containing lipoproteins, resulting in significant reduction in atherosclerotic complications and total mortality in trials. Recent research indicates novel major target sites of action in the liver to 1) directly inhibit diacylglycerol acyltransferase 2 (DGAT2), explaining its effect on triglycerides and apo B lipoproteins, and 2) inhibit the HDL apo AI catabolism pathway, resulting in higher HDL levels. Such information may lead to new drug discovery and supply the rationale for combination with other lipid regulators that are known to have different mechanisms of action. Trial evidence shows that niacin is not only safe to use in persons with diabetes, but that its combination with 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) is also safe and effective. Recently, a new formulation of niacin has made it easier to tolerate and administer. Clinical trials are needed to determine whether niacin in combination with other lipidmodulating agents decreases the risk of cardiovascular events beyond the approximately 30% that has been noted with monotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals. Edited by Budavari S, O’Neil MJ, Smith A, Heckelman PE. Whitehouse Station, NJ: Merck Publishing Group; 1989:1030–1031.

    Google Scholar 

  2. Morgan MM, Capuzzi DM, Guyton JR: A new extended release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998, 82:29U-34U.

    Article  PubMed  CAS  Google Scholar 

  3. Knopp RH, Alagona P, Davidson M, et al.: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998, 47:1097–1104.

    Article  PubMed  CAS  Google Scholar 

  4. Tavintharan S, Kashyap ML: The benefits of niacin in atherosclerosis. Curr Atherosclerosis Rep 2001, 3:74–82. This review summarizes the effects of niacin on atherogenic and antiatherogenic particles. It also address major clinical trials that have demonstrated niacin’s ability to reduce cardiovascular events.

    CAS  Google Scholar 

  5. Capuzzi DM, Guyton JR, Morgan JM, et al.: Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998, 82:74U-81U.

    Article  PubMed  CAS  Google Scholar 

  6. Guyton JR, Goldberg AC, Kreisberg RA, et al.: Effectiveness of once-daily dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998, 82:737–743.

    Article  PubMed  CAS  Google Scholar 

  7. Sakai T, Kamanna VS, Kashyap ML: Niacin but not gemfibrozil increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 2001, 21:1783–1789. This paper showed niacin’s selective mechanism in increase antiatherogenic particles.

    PubMed  CAS  Google Scholar 

  8. Knopp RH, Alagona P, Davidson M, et al.: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998, 47:1097–1104.

    Article  PubMed  CAS  Google Scholar 

  9. Mckenney JM, Proctor JD, Harris S, Chinchili VM: A comparison of the efficacy and toxic effects of sustained- vs. immediaterelease niacin in hypercholesterolemic patients. JAMA 1994, 271:672–677.

    Article  PubMed  CAS  Google Scholar 

  10. Knopp RH, Ginsberg J, Albers JJ, et al.: Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues of mechanism of action of niacin. Metabolism 1985, 34:642–650.

    Article  PubMed  CAS  Google Scholar 

  11. Stern RH, Freeman D, Spence JD: Differences in metabolism of time-release and unmodified nicotinic acid: explanation of the differences in hypolipidemic action. Metabolism 1992, 41:879–881.

    Article  PubMed  CAS  Google Scholar 

  12. Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987, 257:3233–3240.

    Article  PubMed  CAS  Google Scholar 

  13. Knopp RH: Evaluating niacin in its various forms. Am J Cardiol 2000, 86(Suppl):51L-56L.

    Article  PubMed  CAS  Google Scholar 

  14. Advicor prescribing information. Miami: Kos Pharmaceuticals; 2001.

  15. Superko HR, Krauss RM: Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 1992, 95:69–76.

    Article  PubMed  CAS  Google Scholar 

  16. McKenney JM, McCormick LS, Schaeffer EJ, et al.: Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 2001, 88:270–274.

    Article  PubMed  CAS  Google Scholar 

  17. Kashyap ML, McGovern ME, Berra K, et al.: Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002 89:672–678. This study demonstrated that the combination of niacin with a statin was both safe and effective, with very few side effects.

    Article  PubMed  CAS  Google Scholar 

  18. Guyton JR, Blazing BA, Hagar J, et al., for the Niaspan-Gemfibrozil Study Group: Extended release niacin vs. gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med 2000, 160:1177–1184.

    Article  PubMed  CAS  Google Scholar 

  19. Garg R, Malinow M, Pettinger M, et al.: Niacin treatment increase plasma homocyst(e)ine levels. Am Heart J 1999, 138:1082–1087.

    Article  PubMed  CAS  Google Scholar 

  20. Magoni AA, Jackson SH: Homocysteine and cardiovascular disease: Current perspective and future prospects. Am J Med 2002, 112:556–565.

    Article  Google Scholar 

  21. Altschul R, Hoffer A, Stephen JD: Influence of nicotinic acid on serum cholesterol in man. Arch Bioch Biophys 1955, 54:558–559.

    Article  CAS  Google Scholar 

  22. Carlson LA: Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand 1963, 173:719–722.

    Article  PubMed  CAS  Google Scholar 

  23. Wise A, Foord SM, Fraser NJ, et al.: Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003, 278:9869–9874.

    Article  PubMed  CAS  Google Scholar 

  24. Tunaru S, Kero J, Schuab A, et al.: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003, 9:352–355.

    Article  PubMed  CAS  Google Scholar 

  25. Jin FY, Kamanna VS, Kashyap ML: Niacin accelerates intracellular apo B degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (Hep G2) cells. Arterioscler Thromb Vasc Biol, 1999, 19:1051–1059. This study alluded to the mechanism by which niacin reduces plasma triglyceride and VLDL cholesterol levels.

    PubMed  CAS  Google Scholar 

  26. Ganji SH, Tavintharan S, Zhu D, et al.: Niacin non-competitively inhibits hepatocyte diacylglycerol acyltransferase, a key enzyme for triglyceride synthesis [abstract]. Arterioscler Thromb Vasc Biol 2002, 22:878A. This study identified the enzyme that is directly inhibited by niacin. This enzyme is involved in the final step of triglyceride synthesis, thereby providing another mechanism of action of niacin in lowering triglycerides.

    Google Scholar 

  27. Kamanna VS, Kashyap ML: Mechanism of action of niacin on lipoprotein metabolism. Curr Artherosclerosis Rep 2000, 2:36–46.

    CAS  Google Scholar 

  28. Blum CB, Levy JU, Eisenberg S, et al.: High density lipoprotein metabolism in man. J Clinc Invest 1977, 60:795–807.

    CAS  Google Scholar 

  29. Shepherd J, Packard CJ, Patsch JR, et al.: Effect of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979, 63:858–867.

    PubMed  CAS  Google Scholar 

  30. Jin FY, Kammana VS, Kashyap ML: Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997, 17:2020–2028.

    PubMed  CAS  Google Scholar 

  31. Martinez LD, Jacquet S, Esteve JP, et al.: Ectopic b-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003, 421:75–79. This article reports on the identification of the holoparticle catabolism receptor, which is inhibited by niacin. Inhibition of this receptor leads to longer half-life of HDL cholesterol. This discovery has many implications in discovery of novel HDL cholesterol-increasing drugs.

    Article  PubMed  CAS  Google Scholar 

  32. Moestrup SK, Kozyraki R: Cubilin, a high-density lipoprotein receptor. Curr Opin Lipidol 2000, 11:133–140.

    Article  PubMed  CAS  Google Scholar 

  33. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360–381.

    Article  Google Scholar 

  34. Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245–1255.

    Article  PubMed  CAS  Google Scholar 

  35. Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405–418.

    Article  PubMed  CAS  Google Scholar 

  36. Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987, 257:3233–3240.

    Article  PubMed  CAS  Google Scholar 

  37. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al.: Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990, 264:3013–3017.

    Article  PubMed  CAS  Google Scholar 

  38. Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289–1298.

    Article  PubMed  CAS  Google Scholar 

  39. Kane JP, Malloy MJ, Ports TA, et al.: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990, 264:3007–3012.

    Article  PubMed  CAS  Google Scholar 

  40. Brown BG, Zhao X-Q, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592; editorial 1636–1637. This study is the first to show that cardiovascular events can be reduced at least two times as much with combination therapy versus monotherapy of dyslipidemia.

    Article  PubMed  CAS  Google Scholar 

  41. Elam MB, Hunninghake DB, Davis KB, et al: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral vascular disease. The ADMIT study, a randomized trial. JAMA 2000, 284:1263–1270.

    Article  PubMed  CAS  Google Scholar 

  42. Grundy SM, Vega GL, McGovern ME et al.: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002, 162:1568–1576. This study showed that niacin safe and effective in persons with diabetes.

    Article  PubMed  CAS  Google Scholar 

  43. Canner PL, Furberg CD, Terrin ML, McGovern ME: Niacin decreases myocardial infarction and total mortality in patients with metabolic syndrome: results from the coronary drug project [abstract]. J Amer Coll Card 2003, 41A. This presentation demonstrated that niacin may actually have a greater benefit in terms of cardiovascular events and mortality in those with high baseline glucose levels and in those with metabolic syndrome.

  44. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282:2340–2346.

    Article  PubMed  CAS  Google Scholar 

  45. Rubins HB, Robins SJ, Collins D, et al.: Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol 1995, 75:1196–1201.

    Article  PubMed  CAS  Google Scholar 

  46. Martin G, Duez H, Blanquart C, et al.: Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001, 107:1423–1432.

    Article  PubMed  CAS  Google Scholar 

  47. Qin S, Koga T, Ganji SH, et al.: Rosuvastatin stimulates apolipoprotein-AI synthesis but not HDL catabolism by human hepatoblastoma cells (Hep G2). Poster presented at the 4th annual Arteriosclerosis, Thrombosis, and Vascular Biology meeting. Washington, DC: May 8–10, 2003.

  48. Bays HE, Dujovne CA, McGovern ME, et al.: Advicor versus other cholesterol-modulating agents trial evaluation. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003, 91:667–672. This study demonstrates that combination therapy with niacin and a statin is more effective in improving the lipid profile than monotherapy with a statin.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Division of Cardiology, University of California at Irvine, 5901 East Seventh Street (11-111-I), 90822, Long Beach, CA, USA

    Moti L. Kashyap MD

Authors
  1. Shaista Malik MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Moti L. Kashyap MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Malik, S., Kashyap, M.L. Niacin, lipids, and heart disease. Curr Cardiol Rep 5, 470–476 (2003). https://doi.org/10.1007/s11886-003-0109-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-003-0109-x

Keywords

Search

Navigation